A comprehensive overview of selective and novel fibroblast growth factor receptor inhibitors as a potential anticancer modality

A comprehensive overview of selective and novel fibroblast growth factor receptor inhibitors as a potential anticancer modality

The arrival of comprehensive genome sequencing has accelerated the understanding of genetically aberrant advanced cancers and target identification for possible cancer treatment. Fibroblast growth factor receptor (FGFR) gene alterations are frequent findings in various rare and advanced cancers refr...

Full description

Saved in:
Bibliographic Details
Main Authors: Jain Nem Kumar, Tailang Mukul, Thangavel Neelaveni, Makeen Hafiz A., Albratty Mohammed, Najmi Asim, Alhazmi Hassan Ahmad, Zoghebi Khalid, Alagusundaram Muthumanickam, Jain Hemant Kumar, Chandrasekaran Balakumar
Format: Article
Language:English
Published: Sciendo 2024-03-01
Series:Acta Pharmaceutica
Subjects:
fgfr
tyrosine kinase inhibitors
fda approval
erdafitinib
infigratinib
pemigatinib
futibatinib
Online Access:https://doi.org/10.2478/acph-2024-0005
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.2478/acph-2024-0005

Similar Items